RivaCap 3 mg (Capsule)
Unit Price: ৳ 22.00 (1 x 10: ৳ 220.00)
Strip Price: ৳ 220.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Rivastigmine tartrate |
| Company | Ibn sina pharmaceuticals ltd |
| Also available as |
Indications
- Symptomatic treatment of mild to moderately severe Alzheimer's dementia
- Symptomatic treatment of mild to moderately severe dementia in patients with Idiopathic Parkinson's disease
Pharmacology
- Carbamate derivative
- Structurally related to physostigmine
- Binds reversibly with and inactivates cholinesterase
- Increases concentration of acetylcholine at cholinergic synapses
- Relatively specific for brain acetylcholinesterase and butyrylcholinesterase
Dosage
- Rivastigmine capsule initial dose: 1.5 mg twice a day
- Rivastigmine capsule maintenance dose: 3 mg to 6 mg twice a day
- Rivastigmine transdermal patch initial dose: 4.6 mg/24 hours
- Rivastigmine transdermal patch maximum dosage: 13.3 mg/24 hours
Administration
- Twice a day with morning and evening meals
Interaction
- Exaggerates the effects of succinylcholine-type muscle relaxants during anesthesia
- Should not be given concomitantly with other cholinomimetic substances
- Might interfere with the activity of anticholinergic medicinal products
Contraindications
- Hypersensitivity to the active substance or other carbamate derivatives
Side Effects
- Nausea (38%)
- Vomiting (23%)
- Gastrointestinal adverse reactions
- Weight loss, especially in female patients
Pregnancy & Lactation
- Not recommended during pregnancy
- Excreted into milk
- Women on rivastigmine should not breast-feed
Precautions & Warnings
- Patients with sick sinus syndrome or conduction defects
- Cholinergic stimulation may increase gastric acid secretion
- May exacerbate urinary obstruction and seizures
- Monitor body weight
- May worsen extrapyramidal symptoms
Use in Special Populations
- Increased exposure in moderate renal and mild to moderate hepatic impairment
- Not recommended for use in children
Overdose Effects
- Accidental overdose not associated with clinical signs or symptoms
- Nausea, vomiting, diarrhea, hypertension, hallucinations
- Bradycardia and/or syncope may occur
- Plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours
- Ingestion of 46 mg occurred in one case; patient fully recovered within 24 hours
Therapeutic Class
- Drugs for Dementia
Storage Conditions
- Cool and dry place
- Protected from light